Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals ($APLS), made three open market sales of company shares over the past year, totaling nearly $198,000. His most recent sale occurred on January 22, 2026. These transactions rank 8,448th out of 11,678 insiders in our database, well below the average sale value of 8.6 million and 6.4 transactions per insider. Deschatelets had no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 28, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | A | Common Stock | 25840 | $0.00 | 1,177,222.0000 | 130,067,000 | 2.24% | 0.02% |
| Jan. 22, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 5928 | $21.77 | 1,151,382.0000 | 130,067,000 | 0.51% | 0.00% |
| Jan. 20, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 909 | $19.79 | 1,157,310.0000 | 130,067,000 | 0.08% | 0.00% |
| Jan. 13, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 2277 | $22.19 | 1,158,219.0000 | 130,067,000 | 0.20% | 0.00% |
| June 9, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | A | Stock Option (Right to Buy) | 82500 | $19.39 | 82,500.0000 | 123,905,000 | 9999.99% | 0.07% |
| May 21, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Common Stock | 12780 | $3.76 | 1,160,496.0000 | 123,905,000 | 1.11% | 0.01% |
| May 21, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Stock Option (Right to Buy) | 12780 | $0.00 | 0.0000 | 123,905,000 | 100.00% | 0.01% |
| Jan. 29, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 826 | $29.52 | 1,147,716.0000 | 123,905,000 | 0.07% | 0.00% |
| Jan. 22, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 3948 | $30.43 | 1,148,542.0000 | 123,905,000 | 0.34% | 0.00% |
| Jan. 17, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 750 | $29.96 | 1,137,445.0000 | 123,905,000 | 0.07% | 0.00% |
| Jan. 21, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | A | Common Stock | 15045 | $0.00 | 1,152,490.0000 | 123,905,000 | 1.32% | 0.01% |
| Jan. 13, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 2288 | $28.70 | 1,138,195.0000 | 123,905,000 | 0.20% | 0.00% |
| May 20, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Stock Option (Right to Buy) | 24500 | $0.00 | 12,780.0000 | 118,678,000 | 65.72% | 0.02% |
| May 20, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Common Stock | 24500 | $3.76 | 1,140,483.0000 | 118,678,000 | 2.20% | 0.02% |
| May 8, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Stock Option (Right to Buy) | 78907 | $0.00 | 108,622.0000 | 118,678,000 | 42.08% | 0.07% |
| May 8, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Common Stock | 78907 | $4.31 | 1,194,890.0000 | 118,678,000 | 7.07% | 0.07% |
| May 8, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 22472 | $42.85 | 1,116,083.0000 | 118,678,000 | 1.97% | 0.02% |
| May 8, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 56335 | $42.15 | 1,138,555.0000 | 118,678,000 | 4.71% | 0.05% |
| May 8, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 100 | $44.03 | 1,115,983.0000 | 118,678,000 | 0.01% | 0.00% |
| April 8, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Common Stock | 69107 | $3.76 | 1,185,090.0000 | 118,678,000 | 6.19% | 0.06% |
| April 8, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 64379 | $54.12 | 1,120,711.0000 | 118,678,000 | 5.43% | 0.05% |
| April 8, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 4728 | $54.92 | 1,115,983.0000 | 118,678,000 | 0.42% | 0.00% |
| April 8, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Stock Option (Right to Buy) | 69107 | $0.00 | 37,280.0000 | 118,678,000 | 64.96% | 0.06% |
| March 8, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 26257 | $62.69 | 1,116,083.0000 | 118,678,000 | 2.30% | 0.02% |
| March 8, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Common Stock | 69107 | $3.67 | 1,185,090.0000 | 118,678,000 | 6.19% | 0.06% |
| March 8, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 42750 | $61.88 | 1,142,340.0000 | 118,678,000 | 3.61% | 0.04% |
| March 8, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 100 | $63.35 | 1,115,983.0000 | 118,678,000 | 0.01% | 0.00% |
| March 8, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Stock Option (Right to Buy) | 69107 | $0.00 | 106,387.0000 | 118,678,000 | 39.38% | 0.06% |
| Feb. 12, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 1148 | $67.77 | 1,115,983.0000 | 118,678,000 | 0.10% | 0.00% |
| Jan. 29, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 874 | $64.14 | 1,117,131.0000 | 118,678,000 | 0.08% | 0.00% |
| Jan. 22, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 3913 | $65.00 | 1,118,005.0000 | 118,678,000 | 0.35% | 0.00% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 1632 | $66.81 | 1,121,918.0000 | 118,678,000 | 0.15% | 0.00% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | A | Stock Option (Right to Buy) | 9805 | $66.30 | 9,805.0000 | 118,678,000 | 9999.99% | 0.01% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | A | Common Stock | 6743 | $0.00 | 1,123,550.0000 | 118,678,000 | 0.60% | 0.01% |
| Nov. 14, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Common Stock | 45000 | $3.76 | 1,116,807.0000 | 106,114,000 | 4.20% | 0.04% |
| Nov. 14, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Stock Option (Right to Buy) | 45000 | $0.00 | 175,494.0000 | 106,114,000 | 20.41% | 0.04% |
| Nov. 8, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 12000 | $47.27 | 1,071,807.0000 | 106,114,000 | 1.11% | 0.01% |
| Nov. 8, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Common Stock | 17494 | $2.67 | 1,083,807.0000 | 106,114,000 | 1.64% | 0.02% |
| Nov. 8, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Stock Option (Right to Buy) | 17494 | $0.00 | 0.0000 | 106,114,000 | 100.00% | 0.02% |
| Oct. 9, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Common Stock | 18500 | $2.67 | 1,078,313.0000 | 106,114,000 | 1.75% | 0.02% |
| Oct. 9, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Stock Option (Right to Buy) | 18500 | $0.00 | 17,494.0000 | 106,114,000 | 51.40% | 0.02% |
| Oct. 9, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 12000 | $40.38 | 1,066,313.0000 | 106,114,000 | 1.11% | 0.01% |
| Sept. 8, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Common Stock | 18500 | $2.67 | 1,071,813.0000 | 106,114,000 | 1.76% | 0.02% |
| Sept. 8, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 12000 | $42.87 | 1,059,813.0000 | 106,114,000 | 1.12% | 0.01% |
| Sept. 8, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Stock Option (Right to Buy) | 18500 | $0.00 | 35,994.0000 | 106,114,000 | 33.95% | 0.02% |
| Aug. 8, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 12000 | $23.66 | 1,053,313.0000 | 106,114,000 | 1.13% | 0.01% |
| Aug. 8, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Stock Option (Right to Buy) | 18500 | $0.00 | 54,494.0000 | 106,114,000 | 25.34% | 0.02% |
| Aug. 8, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Common Stock | 18500 | $2.67 | 1,065,313.0000 | 106,114,000 | 1.77% | 0.02% |
| July 10, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 12000 | $84.55 | 1,046,813.0000 | 106,114,000 | 1.13% | 0.01% |
| July 10, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Stock Option (Right to Buy) | 18500 | $0.00 | 72,994.0000 | 106,114,000 | 20.22% | 0.02% |
| July 10, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Common Stock | 18500 | $2.67 | 1,058,813.0000 | 106,114,000 | 1.78% | 0.02% |
| June 8, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Stock Option (Right to Buy) | 18500 | $0.00 | 91,494.0000 | 106,114,000 | 16.82% | 0.02% |
| June 8, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Common Stock | 18500 | $2.67 | 1,052,313.0000 | 106,114,000 | 1.79% | 0.02% |
| June 8, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 12000 | $91.35 | 1,040,313.0000 | 106,114,000 | 1.14% | 0.01% |
| May 8, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 12000 | $92.39 | 1,033,813.0000 | 106,114,000 | 1.15% | 0.01% |
| May 8, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Stock Option (Right to Buy) | 18500 | $0.00 | 109,994.0000 | 106,114,000 | 14.40% | 0.02% |
| May 8, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Common Stock | 18500 | $2.67 | 1,045,813.0000 | 106,114,000 | 1.80% | 0.02% |
| April 10, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 12000 | $78.21 | 1,027,313.0000 | 106,114,000 | 1.15% | 0.01% |
| April 10, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Stock Option (Right to Buy) | 18500 | $0.00 | 128,494.0000 | 106,114,000 | 12.59% | 0.02% |
| April 10, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Common Stock | 18500 | $2.67 | 1,039,313.0000 | 106,114,000 | 1.81% | 0.02% |
| March 8, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 12000 | $63.79 | 1,020,813.0000 | 106,114,000 | 1.16% | 0.01% |
| March 8, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Stock Option (Right to Buy) | 18500 | $0.00 | 146,994.0000 | 106,114,000 | 11.18% | 0.02% |
| March 8, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Common Stock | 18500 | $2.67 | 1,032,813.0000 | 106,114,000 | 1.82% | 0.02% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | A | Common Stock | 9886 | $0.00 | 1,015,508.0000 | 106,114,000 | 0.98% | 0.01% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | F | Common Stock | 1195 | $58.50 | 1,014,313.0000 | 106,114,000 | 0.12% | 0.00% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | A | Stock Option (Right to Buy) | 14023 | $0.00 | 14,023.0000 | 106,114,000 | 9999.99% | 0.01% |
| Feb. 10, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | F | Common Stock | 1134 | $51.21 | 1,005,622.0000 | 106,114,000 | 0.11% | 0.00% |
| Feb. 8, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Common Stock | 18500 | $2.67 | 1,018,756.0000 | 106,114,000 | 1.85% | 0.02% |
| Feb. 8, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 12000 | $54.45 | 1,006,756.0000 | 106,114,000 | 1.18% | 0.01% |
| Feb. 8, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Stock Option (Right to Buy) | 18500 | $0.00 | 165,494.0000 | 106,114,000 | 10.05% | 0.02% |
| Jan. 27, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | F | Common Stock | 832 | $52.77 | 1,000,256.0000 | 106,114,000 | 0.08% | 0.00% |
| Jan. 20, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | F | Common Stock | 2326 | $52.05 | 1,001,088.0000 | 106,114,000 | 0.23% | 0.00% |
| Jan. 12, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | A | Stock Option (Right to Buy) | 30845 | $52.66 | 30,845.0000 | 106,114,000 | 9999.99% | 0.03% |
| Jan. 12, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | A | Common Stock | 19634 | $0.00 | 1,003,414.0000 | 106,114,000 | 2.00% | 0.02% |
| Jan. 9, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | S | Common Stock | 12000 | $46.08 | 983,780.0000 | 106,114,000 | 1.21% | 0.01% |
| Jan. 9, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Stock Option (Right to Buy) | 18500 | $0.00 | 183,994.0000 | 106,114,000 | 9.14% | 0.02% |
| Jan. 9, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Deschatelets Pascal | Chief Scientific Officer | M | Common Stock | 18500 | $2.67 | 995,780.0000 | 106,114,000 | 1.89% | 0.02% |